Trial Profile
A Phase II Study of Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 16 Feb 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 31 Mar 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 13 Mar 2009 New trial record